Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics

Robert Kubina 1,* and Arkadiusz Dziedzic 2

1 Department of Pathology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland
2 Department of Conservative Dentistry with Endodontics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland; adziedzic@sum.edu.pl

* Correspondence: rkubina@sum.edu.pl; Tel.: +48-32-3641354

Received: 9 May 2020; Accepted: 24 June 2020; Published: 26 June 2020

Abstract: Validated and accurate laboratory testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a crucial part of the timely management of Coronavirus Disease 2019 (COVID-19) disease, supporting the clinical decision-making process for infection control at the healthcare level and detecting asymptomatic cases. This would facilitate an appropriate treatment, a prompt isolation and consequently deceleration of the pandemic. Various laboratory tests can identify the genetic material of SARS-CoV-2 that causes COVID-19 in specimens, or specific anti-viral antibodies in blood/serum. Due to the current pandemic situation, a development of point-of-care (POC) diagnostics allows us to substantially accelerate taking clinical decisions and implement strategic planning at the national level of preventative measures. This review summarizes and compares the available POC and those currently under development, including quantitative reverse transcription PCR (RT-qPCR), serology immunoassays (SIAs) and protein microarray method (PMM) designed for standard and rapid COVID-19 diagnosis.

Keywords: COVID-19; SARS-CoV-2; in vitro diagnostic tests; RT-qPCR; serology immunoassays

1. Introduction

Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV), appeared in China for the first time, and subsequently spread worldwide [1,2]. On 30 January 2020, the World Health Organization (WHO) officially announced the COVID-19 epidemics as a threat to public health internationally, and subsequently, in March 2020, the global situation escalated into the COVID-19 pandemic. Johns Hopkins University reported over 7,600,000 cases of infection and more than 427,000 deaths as of 13 June 2020 [3]. As a result of this rapidly progressing COVID-19 pandemic and the limited laboratory-based molecular testing capacities, new point-of-care (POC), scalable rapid diagnostic tests have been invented recently as easy-to-use tools to allow COVID-19 diagnostics outside of laboratory settings. What is more, the urgent need to multiply testing for COVID-19 has been clearly identified as an essential element of the anti-coronavirus strategy all over the world.

The diagnostic sensitivity, specificity and accuracy concerning suspected COVID-19 infection, based on controlled testing and performance data from clinical settings, is of substantial importance in the context of limiting the scope of coronavirus epidemics. Unreliable and unproved tests may not detect patients with active infection or may incorrectly indicate COVID-19-negative patients as positive, hampering healthcare efforts. The diagnostic laboratory and point-of-care tests (POCTs)
used in order to detect SARS-CoV-2 are, first of all, reference tests based on molecular technique real-time quantitative reverse transcriptase polymerase chain reaction assay (RT-qPCR) as well as serological antibody-detecting and antigen-detecting tests, for auxiliary purposes. At present, only molecular quantitative reverse transcription PCR (RT-qPCR) testing of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases, as these methods were evaluated for their quality and safety through the World Health Organization (WHO) protocols [4,5]. On the other hand, based on current scientific evidence, WHO recommends the use of POC immunodiagnostic tests for research purposes and, at present, they should not be utilized in a clinical decision-making setting and in patient care until fully validated, with supporting data available. However, they can be useful in epidemiologic research or disease surveillance and further evolve as a critical step to develop COVID-19 vaccine in future. At the time of increased demand for hospital services, clinicians, governments and health services urgently need a fast, sensitive, but at the same time inexpensive diagnostic test, in order to rapidly manage patients, regarding admissions to hospitals meant for COVID-19 treatment. Therefore, the role of an approved and reliable diagnostic test in the COVID-19 care pathway is of the utmost importance.

As in the case of other infectious diseases, the RT-qPCR method, as well as serological tests, are suitable for the in vitro diagnostics (IVD) of patients suspected of being infected with SARS-CoV-2. Genetic assay based on the RT-qPCR technique, performed in real time, especially plays a role at the early stages of viral infection, when the virus multiplies quickly, as this technique enables direct detection of the pathogen’s genetic material. A different approach in diagnosing infection is represented by serological methods, based on detecting—in blood serum—of antibodies that act specifically against viral proteins, which are produced in response to SARS-CoV-2. Serological IVD tests detect antibodies which are responsible for neutralizing the virus; therefore, this implies that they are used when the immunological reaction against SARS-CoV-2 virus is already taking place. These IVD measures can determine how fast antibodies fighting the virus are produced, which may influence the identification of subjects who already developed immunity. The results of serological IVD tests should not be used as basis for diagnosing, ruling out infection with SARS-CoV-2, or informing about infection status [6].

The relatively quick discovery of the composition of the full genome of SARS-CoV-2 early during the epidemics made it easier to develop specific starters and normalized laboratory protocols for COVID-19. The protocol of the first RT-qPCR test, focused on RNA-dependent RNA polymerase (RdRp), envelope (E) and nucleocapsid (N) of SARS-CoV-2 was published very early indeed, at the end of January 2020. Providing a brief description, the novel coronavirus SARS-CoV-2 is equipped with a receptor-binding domain (RBD), a structure similar to the 'original' SARS-CoV that emerged for the first time in 2002. Functionally important ORFs (1a and 1b) and other main structural proteins, including the spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins, are also well interrelated and clearly annotated. According to previous reports, the M and E proteins are essential for virus assembly, while the S protein is crucial for affinity and attachment to host cells, as the RBD of the S protein enables binding with angiotensin-converting enzyme 2 (ACE2). The S protein on the surface of the viral particles and has been reported to be highly immunogenic. The N protein, the main structural protein of SARS-CoV-2 is responsible for the transcription and replication of viral RNA, the packaging of the encapsulated genome into virions, and interactions with the cell cycle of host cells. In addition, coronaviruses contain the N protein, which has a substantial immunogenic ability and is abundantly expressed during viral infection (Figure 1). The S/N proteins are targeted as potential antigens for serodiagnosis of COVID-19, similarly to other diagnostic methods that were implemented for diagnosing SARS disease, based on S/N proteins [7].
2. Reference Molecular RT-qPCR Assay for Validated COVID-19 Diagnosis

At present, work is going on worldwide to develop new methods which will simplify and speed up the detection of novel coronavirus. Currently, there are nearly 200 commercially available genetic tests, with further companies awaiting the completion of the procedure and Food and Drug Administration (FDA) or In Vitro Diagnostics (IVD) certificate to be issued. It is worth noting that a large portion of available tests are provided merely with the Research Use Only (RUO) certificate, which in fact does not imply anything concerning test quality or its validation. More rigorous tests apply to products certified as IVD, complying with the ISO13485 norm. In addition, IVD reagents are subject to local regulations, such as CE marking in Europe, and hence they should comply with Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices, with an extensive evaluation, including the validation of clinical samples.

Real Time RT-qPCR genetic tests are meant for the identification and differentiation of SARS-CoV-2 in the material/specimens collected from patients with COVID-19 symptoms, by detecting RNA sequences unique for SARS-CoV-2. The genetic material of the virus is extracted from specimens (sputum, tracheal aspirate or bronchoalveolar lavage, swabs from nasopharynx and pharynx, blood, urine, or stool) and amplified by means of the PCR technique in real time, with the use of reverse transcription (RT), and detected by means of fluorescent reporter probes specific to SARS-CoV-2 [8,9].

At present, RT-qPCR tests are available in the world market, which are meant to detect ORF1ab, E, N, or S gene sequences, in various combinations. Those tests differ in sensitivity, stability, and examination time. The test protocol is complex and costly, being mainly suitable for large, centralized diagnostic laboratories. Tests usually take 4–6 h, yet the logistic requirements concerning sending clinical specimens imply that execution time is 24 h at the most [10].

In accordance with WHO recommendations, RT-qPCR tests must enable the detection of three genes in a single reaction: E gene, N gene, and RdRP gene. This allows us to detect viruses from the beta-coronavirus group (E gene), as well as to identify SARS-CoV-2 virus (N gene and RdRP, ORF1ab). Such a design guarantees double confirmation in cases of infection, it also limits the risk of obtaining false negative results in case of detecting only one target for SARS-CoV-2. This reduces the possibility of obtaining doubtful results, in which case the necessity of verification occurs [11]. A comparison review of RT-qPCR dedicated to SARS-CoV-2 genes target points is presented in Table 1.
Table 1. Comparison of RT-qPCR dedicated for SARS-CoV-2 genes target points [12] (updated 13 June 2020, online sources).

| Developer            | Name of the Kit                                      | Gene                  | Regulatory                        |
|----------------------|------------------------------------------------------|-----------------------|-----------------------------------|
| 1drop Inc.           | 1copy™ COVID-19 qPCR Kit                            | ORF1a, ORF1ab, RdRP, E | CE-IVD                            |
| AB ANALITICA srl     | REALQUALITY RQ-2019-nCoV RT-PCR Kit 1.0             |                       | CE-IVD                            |
| ADT Biotech          | LyteStar 2019-nCoV RT-PCR Kit                        |                       | RUO                               |
| altona Diagnostics   | RealStar® SARS-CoV-2 RT-PCR Kit                      |                       | USA EUA, CE-IVD                   |
| Atla Biosystems Inc. | Atla iAMP® COVID Detection Kit                       |                       | USA EUA, CE-IVD; RUO             |
| BIOMAXIMA S.A.       | SARS-CoV-2 Real Time PCR LAB-KIT™                    |                       | CE-IVD                            |
| bioMérieux           | AccuVY™ SARS-CoV-2 R-GENE®                          |                       | USA EUA, CE-IVD                   |
| Bioneer              | Real-Time RT-PCR                                    |                       | CE-IVD                            |
| BGI Health (HK)      | Real-time fluorescent RT-PCR kit 2019-nCoV          |                       | USA EUA, CE-IVD, Canada           |
| CerTest Biotec, S.L. | VIASURE SARS-CoV-2 Real Time PCR Kit                 |                       | CE-IVD                            |
| CerTest Biotec, S.L. | VIASURE SARS-CoV-2 S gene Real Time PCR Kit         |                       | CE-IVD                            |
| Co-diagnostics       | LogicSmart Coronavirus disease 2019                 |                       | CE-IVD                            |
| CTK Biotech, Inc.    | Aridia COVID-19 Real Time PCR Test                   |                       | CE-IVD                            |
| DAAN Gene Co         | Detection Kit for 2019 Novel Coronavirus             |                       | CE-IVD; China                     |
| Edinburgh Genetics   | COVID-19 Real-time PCR Testing Kit                   |                       | CE-IVD; China FDA                 |
| Gencurius Inc.       | GenePro COVID-19 Detection Test                      |                       | CE-IVD                            |
| Genomictech, Inc.    | AccuraTest RT-qPCR SARS-CoV-2                       |                       | CE-IVD                            |
| KH Medical           | RADI COVID-19 Detection Kit                          |                       | CE-IVD                            |
| KRISHGEN             | SARS-CoV-2 (COVID-19) Real-Time PCR Kit             |                       | RUO                               |
| Liming Bio-Products  | StrongStep® Novel Coronavirus (SARS-CoV-2)          |                       | CE-IVD                            |
| PerkinElmer Inc.     | PerkinElmer® SARS-CoV-2 Realtime RT-PCR             |                       | CE-IVD, WHO-EUL                   |
| Primerdesign Ltd.    | COVID-19 genotyping Real-Time PCR assay              |                       | CE-IVD; USA EUA,WHO EUL           |
| R-Biopharm AG        | RIDA® GENE SARS-CoV-2 RUO (PG6815RUO)                |                       | RUO                               |
| SD BIOSENSOR Inc.    | STANDARD M nCoV Real-Time Detection Kit             |                       | CE-IVD, USA EUA; Brazil           |
| TIB/Roche Diagn.     | LightMix Modular SARS-CoV-2 (COVID19)               |                       | RUO                               |
| TIB/Roche Diagn.     | LightMix Modular SARS-CoV-2 (COVID19)               |                       | RUO                               |
| TIB/Roche Diagn.     | LightMix Modular SARS-CoV-2 (COVID19)               |                       | RUO                               |
| SD BIOSENSOR         | STANDARD M nCoV Real-Time Detection kit             |                       | USA EUA, CE-IVD; Brazil           |
| Seegene, Inc.        | Allplex 2019-nCoV assay                             |                       | USA EUA, CE-IVD, Canada           |
| Sanaure Biotech Inc. | Novel Coronavirus (2019-nCoV) Real-Time RT-PCR      |                       | USA EUA, CE-IVD                   |
| Sente Biolab Sentelig| COVID-19 qRT PCR Detection Kit                      |                       | CE-IVD                            |
| Shanghai ZJ BioTech  | Liferiver Novel Coronavirus Multiplex RT-PCR        |                       | CE-IVD, China FDA                 |
| Thermo Fisher        | TaqPath™ COVID-19 CE-IVD RT-PCR Kit                 |                       | CE-IVD                            |
Table 1. Cont.

| Developer                     | Name of the Kit                                      | Gene       | Regulatory              |
|-------------------------------|------------------------------------------------------|------------|-------------------------|
| 3D Biomedicine                | DMed 2019-nCoV RT-qPCR Detection Kit                 | ORF1a, ORF1ab, RdRP | US FDA—CE-IVD            |
| Abbott Molecular Diagnostics  | Abbott RealTime SARS-CoV-2 EUA test                   | E, N, S    | US FDA—CE-IVD            |
| Cepheid                       | Xpert Xpress SARS-CoV-2                              |            | US FDA-EUA              |
| Roche Molecular Diagnostics   | cobas® SARS-CoV-2                                     |            | US FDA—WHO EUL          |
| Sente Biolab                  | Senteligo COVID-19 qRT PCR Detection Kit             |            | CE-IVD                  |
| Solgent Co Ltd                | DiaPlex QP® Novel Coronavirus (2019-nCoV)            |            | CE-IVD                  |
| Star Array Ptd. Ltd.          | 8-min RT-qPCR direct PCR testing                     |            | RUO                     |
| Veredus Laboratories          | VereCoV™ Detection Kit and VerePLEX™                 |            | CE-IVD                  |

The standard protocol with the application of the RT-qPCR method is demanding and time-consuming. For that reason, scientists constantly strive to invent more up to date modifications of the RT-qPCR tests, which would cut down the time required for analyses [13].

Bosch Healthcare Solutions announced that they had developed a quick test, which may provide the results in 2.5 h; it is a fast testing kit for the Vivalytic platform. It is a fully automated PCR test, which is performed by simply inserting the swab into a cartridge, which is subsequently analyzed by the machine. This universal platform for molecular laboratory diagnostics, with the option for various samples testing and different analytical methods, can be carried out as an entirely automated mode within a short time. Unfortunately, the equipment has not been available for many healthcare institutions yet, and the diagnostic cartridges are dedicated solely to the specific analyzing device [14].

BioMaxima has invented a test whose main advantages include a short waiting time; the results can be obtained in a mere 2 h. Moreover, the analytical sensitivity of the test, being at the level of ≥10 RNA copies per reaction, is higher than in other comparable systems. It seems important that the molecular test kit contains reagents with substantially enhanced stability, which allows us to transport it safely and store it at room temperature, whereas many other tests available on the market need to be stored in a freezer and to be transported in dry ice. Storing such reagents, even for a short time, in conditions that deviate from those indicated is risky and may result in generating false negative test results [15].

The latest technology of molecular tests, developed by scientists from Oxford University, is more sensitive than the previous ones and it implies the possibility of examining patients at earlier stages, reacting more quickly, and effectively preventing the spread of coronavirus. This new test for diagnosing SARS-CoV-2 provides rapid results within 30 min, whereas the fastest current methods that concentrate on viral RNA give results in 1.5 to 2 h, i.e., three times faster than the presently quickest testing methods, and which requires the application of relatively simple technical devices. Apart from those advantages, the scientists responsible for the test’s development claim that it may even help detect patients infected with coronavirus at earlier stages, in comparison with current methods, while its results can be read with the “naked eye”, which makes it more available for a wider spectrum of healthcare units and specialists. This fast-molecular test has been recently registered by the FDA and utilizes a diagnostic system, which, in recent years, proved to function perfectly in diagnosing multiple infections (including Hepatitis C Virus—HCV and influenza) [16]. RNA detection may be performed by means of RT-qPCR or reverse transcription–loop amplification (RT–LAMP). A standard RT-qPCR test takes 90 to 120 min on average to test a set of samples, whereas LAMP may be completed in 30 min. Indirect isothermal amplification (LAMP) is a fast technology of DNA amplification, which is applied in the detection of pathogens such as viruses or bacteria. LAMP reaction usually takes place at constant temperature, and the target DNA may be amplified in 30 min. LAMP method utilizes...
four or six starters for binding six regions of target DNA, its specificity is exceptionally high. Because SARS-CoV-2 is a RNA-type virus with a length of some 30 kb, a single reverse transcriptase (RT) reaction and LAMP may, jointly, significantly shorten the reaction time, omitting the stage of purifying cDNA from reverse transcriptase, and thanks to this, SARS-CoV-2 may be quickly detected. It has to be noted that similarly, a one-step RT-qPCR method does not require cDNA purification (a single stage reaction). The team from Oxford University developed four sets of LAMP starters (comprising six starters in each set/kit) focused on viral RNA of SARS-CoV-2 in the regions of ORF1ab, S gene, and N gene. For the interpretation of results, a colorimetric method has been applied, which enables the reading of the results of viral RNA amplification by the naked eye, without the necessity of using expensive equipment. Moreover, the sensitivity of the method may be 80 copies of viral RNA per 1 mL in the sample and single stage process (without separate RNA extraction), which enables the amplification of RNA directly from the sample [17,18].

Performing examinations with the use of fast molecular tests may be particularly useful in Emergency Departments and admission rooms. POCTs are needed to speed up the process of taking clinical decisions and decrease the workload for centralized testing laboratories [16]. POCT means that test results are instantly delivered in the patient care settings, such as hospitals, urgent care centers and emergency rooms, instead of the use of expensive and time-consuming laboratory processes.

Additionally, the American company Cepheid developed a quick test which, as they declare, takes 45 min, while the Dutch pharmacists owning Qiagen developed a 1-h test. The US Food and Drug Administration has issued an emergency authorization of use for Cepheid’s point-of-care COVID-19 diagnostics, Xpert Xpress SARS-CoV-2, according to a statement from the agency. The test was designed to provide detection of novel coronavirus within a short period of 45 min, using specimens from a nasopharyngeal swab, nasal wash/aspirate. Another POCT, the Xpert Xpress SARS-CoV-2 test cartridge is dedicated to detecting SARS-CoV-2 nucleic acid utilizing RT-qPCR and does not require the use of reagents. In the contrary, the GeneXpert System needs the test to be run in a CLIA-approved laboratory (Clinical Laboratory Improvement Amendments) or in a selection of patient care settings [19].

It is equally important to understand that RT-qPCR tests have also certain limitations. They are the most useful in case of positive results, although they appear to have less diagnostic value in situations when COVID-19 must be ruled out. Negative RT-qPCR test results do not necessarily indicate that person has not contracted an infectious disease, as other individual factors also need to be considered, such as exposure risk and potential laboratory errors. The false negative results may occur if the sample has not been properly collected, transported, or handled/treated, or as a result of the improper extraction of nucleic acid from clinical materials [9]. Moreover, the false positive results can be related to the situation where the sample contains inhibitors of amplification, or an insufficient amount of virus molecules. On the contrary, a false positive result may be due to the cross-contamination of the sample during its handling or preparation, or between patient samples. What is more, the influence of vaccines, antiviral drugs, antibiotics, chemotherapeutic agents, or immunosuppressive drugs has not been taken into consideration. Moreover, the set/kit does not exclude diseases caused by other bacterial or viral pathogens. The negative results do not exclude infection and should not be the sole basis for patients’ treatment. Test results when using the kit serve clinical purposes only. Clinical diagnosis and treatment of patients should be considered in conjunction with the manifestations and symptoms, medical history, response to treatment or other laboratory tests [9]. In general, the sensitivity of this molecular method may vary depending on specimen collection (broncho-alveolar lavage, sputum, nasal swabs or throat swabs) and, what is more, the accuracy depends upon stage of infection, the rate of SARS-CoV-2 multiplication, and also the degree of clearance. Interestingly, the provided values of RT-qPCR accuracies seem to be higher for in vitro validation by utilizing SARS-CoV-2-dedicated primers and cultures in highly controlled laboratory settings [20].

It is assumed that the optimal outcome and ‘clear-cut diagnostic gold standard’ might depend upon the development of hybrid assays in order to minimize the fraction of false negative results. The enhanced RT-qPCR test combined with serological immunoassays (either antibody-detecting or
antigen-detecting), would bring an additional diagnostic value for accurate and quick COVID-19 diagnosis in vitro diagnostics, when the human body reacts to an infectious bio-stimulant [21].

**Evaluation of Molecular RT-qPCR Tests that Detect the RNA Nucleic Acid of SARS-CoV-2**

The progress made in recent years in the diagnostics of infections enables the application, often simultaneously, of numerous methods in order to detect respiratory viruses effectively. The choice of suitable tests depends upon the type of virus to be detected, the presumed number of antigens, patient population to be tested, as well as the technical abilities and experience of the testing unit. The validation of RT-qPCR tests seems to be an important step in combating the new coronavirus. One of the most significant parameters regarding the efficiency of the diagnostic procedure is most probably the one related to the minimum amount of analyte, which may be detected and quantitatively determine by means of a particular test. The parameters describing those properties are known as limit of detection (“LoD”) and limit of quantification (“LoQ”). In many laboratories, LoD is used interchangeably with “sensitivity”, “analytical sensitivity”, or/and “detection limit.”. This may be misleading, though, as “sensitivity” is also understood and used in other ways. Sensitivity and clinical (diagnostic) specificity are two different parameters. Diagnostic sensitivity is the proportion of true positive results to the sum of true positive and true negative results. A sensitivity ratio of 100% implies that all the sick people have been identified. The specificity of a test is the proportion of true negative results to the sum of true negative and false positive ones. The specificity of 100% implies that all healthy people in a given test have been correctly identified as healthy/not having the condition.

As indicated in Table 2, sensitivity and specificity of tests is already about 100%, with a few exceptions, still one can notice differences in analytical sensitivity of the test (LOD). The vast majority of molecular tests kits contain a so-called ‘internal positive control’ (IPC), that can be utilized either as an extraction control or internal control. The IPC is essential for an evaluation of whether the genetical material extraction procedure and amplification stage were carried out correctly. The failure in IPC detection using a patient’s specimen may indicate the improper extraction of nucleic acid from clinical material as a consequence of nucleic acid loss or the transposition of PCR inhibitors and the lack of sufficient biological material in the collected sample. It needs to be noted that many molecular tests may not provide sets for extraction stages, and they need to be acquired separately. However, all tests reviewed here that detect the RNA of SARS-CoV-2 contain IPC.

Another important factor which describes a diagnostic test is the analytical specificity. It is the ability of a test to detect a specific target, e.g., a virus. It is of great importance to check whether the starters used in PCR test are specific to a given virus. There are two components of analytical sensitivity: cross-reactivity and interference. Cross-reactivity may occur if, in a sample collected from a patient, there are organisms which are genetically related that imitate the virus analysed, which causes test starters to cross react. As shown in Table 3, the producers have analysed their tests from the perspective of cross-reactivity; unfortunately, that analysis is selective and does not concern the same micro-organisms.
Table 2. The table shows results of independent evaluation to verify the clinical performance of tests. The research was carried out at the University Hospitals of Geneva [12] (updated 13 June 2020, online sources).

| Developer                  | Name of the Kit                                                   | Gene | Clinical Sensitivity | Clinical Specificity | Limit of Detection LOD (Copies/Reaction) |
|----------------------------|-------------------------------------------------------------------|------|----------------------|----------------------|------------------------------------------|
| altona Diagnostics         | RealStar® SARS-CoV-2 RT-PCR Kit 1.0                              | E    | 92%                  | 100%                 | 1–10                                     |
|                            |                                                                   | S    | 92%                  | 100%                 | 1–10                                     |
| Atiła BioSystems Inc.      | Atiła iAMP COVID-19 Detection (isothermal detection)              | ORF1 | 100%                 | 99%                  | 20–100                                   |
|                            |                                                                   | N    | 100%                 | 100%                 | 1–10                                     |
| BGI Health (HK) Co. Ltd.   | Real-time Fluorescent RT-PCR kit for detection 2019-nCoV (CE-IVD) | ORF1 | 100%                 | 99%                  | 1–10                                     |
| bioMérieux                 | ARGENE® SARS-COV-2 R-GENE®                                       | N    | 100%                 | 100%                 | 10–50                                    |
|                            |                                                                   | RDRP | 96%                  | 100%                 | 10–50                                    |
| BIONEER                    | AccuPower® SARS-CoV-2 Real-Time RT-PCR Kit                       | E    | 100%                 | 100%                 | 10–50                                    |
|                            |                                                                   | RDRP | 100%                 | 100%                 | 10–50                                    |
| Boditech Med. Inc.         | ExAmplar COVID-19 real-time PCR kit (L)                         | E    | 100%                 | 100%                 | 10–50                                    |
|                            |                                                                   | RDRP | 90%                  | 100%                 | 50–100                                   |
| CerTest Biotec             | VIASURE SARS-CoV-2 Real Time PCR Detection Kit                   | ORF1 | 98%                  | 100%                 | 10–50                                    |
|                            |                                                                   | N    | 100%                 | 100%                 | 1–10                                     |
| DAAN Gene Co. Ltd.         | Detection Kit for 2019 Novel Coronavirus (2019-nCoV) RNA (PCR-Fluorescence Probing) | ORF1 | 100%                 | 96%                  | 1–10                                     |
|                            |                                                                   | N    | 100%                 | 98%                  | 1–10                                     |
| EUROIMMUN                  | EURORealTime SARS-CoV-2                                         | ORF1 | 100%                 | 98%                  | 1–10                                     |
| Genefirst Ltd.             | The Novel Coronavirus (2019-nCoV) Nucleic Acid Test Kit          | ORF1 | 100%                 | 99%                  | 1–10                                     |
|                            |                                                                   | N    | 98%                  | 100%                 | 1–10                                     |
| KH Medical Co. Ltd.        | RADI COVID-19 Detection Kit                                      | S    | 100%                 | 100%                 | 1–10                                     |
|                            |                                                                   | RDRP | 100%                 | 100%                 | 10–50                                    |
| Primerdesign Ltd.          | Coronavirus COVID-19 genesig® Real-Time PCR assay                | RDRP | 100%                 | 100%                 | 1–10                                     |
| R-Biopharm AG              | RIDA® GENE SARS-CoV-2 RUO                                        | E    | 100%                 | 100%                 | 1–10                                     |
| SD Biosensor Inc.          | STANDARD M nCoV Real-Time Detection Kit                          | E    | 100%                 | 97%                  | 1–10                                     |
|                            |                                                                   | ORF1 | 100%                 | 99%                  | 1–10                                     |
| Seegene Inc.               | Allplex™ 2019-nCoV Assay                                         | E    | 100%                 | 100%                 | 1–10                                     |
|                            |                                                                   | N    | 100%                 | 100%                 | 1–10                                     |
|                            |                                                                   | RDRP | 100%                 | 100%                 | 1–10                                     |
| Shanghai Kehua Bio-Engineering | KHB Diagnostic kit for SARS-CoV-2 Nucleic Acid (Real-time PCR) | ORF1 | 100%                 | 100%                 | 1–10                                     |
|                            |                                                                   | N    | 100%                 | 100%                 | 1–10                                     |
|                            |                                                                   | E    | 100%                 | 100%                 | 1–10                                     |
| Tib Molbiol                | ModularDx Kit SARS-CoV (COVID19) E-gene (Tib Molbiol) + LightCycler Multiplex RNA Virus Master (Roche) | E    | 100%                 | 100%                 | 1–10                                     |
| Vela Diagnostics           | ViroKey™ SARS-CoV-2 RT-PCR Test                                  | RDRP | 94%                  | 100%                 | 10–50                                    |
|                            |                                                                   | ORF1 | 100%                 | 100%                 | 1–10                                     |
### Table 3. The analytical specificity of the test with respect to cross reactivity with other pathogens than Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (updated 13 June 2020, online sources according to manufacturers’ specification).

| Microorganism | 1drop Inc. | Altona Diagnostics | Atilla | CerTest | Co-diagnostics | Edinburgh | Liming | PerkinElmer® | SD BIOSENSOR | Seegene, Inc. | Thermo Fisher | Abbott | Cepheid |
|---------------|------------|--------------------|--------|---------|---------------|-----------|--------|-------------|--------------|---------------|---------------|---------|--------|
| Human coronavirus NL 63 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Human coronavirus OC229E | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Human coronavirus OC43 | - | nd | - | - | - | nd | - | - | - | - | - | - | - | - |
| Human coronavirus HKU1 | - | nd | - | - | - | nd | - | - | - | - | - | - | - | - |
| Human Metapneumovirus (hMPV) | - | - | - | - | nd | nd | nd | nd | - | - | - | - | - | - |
| SARS-coronavirus | - | - | - | - | - | nd | nd | - | - | - | - | - | - | - |
| MERS-coronavirus | - | - | - | - | - | nd | nd | - | - | - | - | - | - | - |
| Parainfluenza virus 1 | - | - | - | - | - | nd | nd | - | - | - | - | - | - | - |
| Parainfluenza virus 2 | - | - | - | - | - | nd | nd | - | - | - | - | - | - | - |
| Parainfluenza virus 3 | - | - | - | - | - | nd | nd | - | - | - | - | - | - | - |
| Parainfluenza virus 4 | - | - | - | - | nd | nd | - | - | - | - | - | - | - | - |
| Influenza A virus | - | - | nd | - | - | - | - | - | - | - | - | - | - | - |
| Influenza B Virus | nd | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Enterovirus (e.g., EV68) | - | - | - | nd | - | nd | nd | - | - | - | - | - | - | - |
| Respiratory syncytial virus A | nd | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Respiratory syncytial virus B | nd | - | - | - | - | nd | - | - | - | - | - | - | - | - |
| Rhinovirus | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Chlamydia pneumoniae | - | - | - | - | - | nd | nd | - | - | - | - | - | - | - |
| Hemophilus influenzae | - | - | nd | - | - | nd | nd | - | - | - | - | - | - | - |
| Legionella pneumophila | - | - | nd | - | - | nd | nd | - | - | - | - | - | - | - |
| Mycobacterium tuberculosis | - | nd | nd | - | - | nd | nd | - | - | - | - | - | - | - |
| Streptococcus pneumoniae | - | - | nd | - | - | nd | - | - | - | - | - | - | - | - |
| Streptococcus pyogenes | - | - | nd | - | nd | nd | - | - | - | - | - | - | - | - |
| Bordetella parapertussis | nd | nd | nd | - | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
| Bordetella bronchiseptica | nd | nd | nd | - | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
| Bordetella pertussis | nd | nd | nd | - | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
| Mycoplasma pneumoniae | - | - | nd | - | - | - | - | - | - | - | - | - | - | - |
| Pneumocystis jiroveci (PJP) | - | - | nd | - | - | nd | nd | - | - | - | - | - | - | - |
| Candida albicans | - | - | nd | - | nd | nd | nd | - | - | - | - | - | - | - |
| Pseudomonas aeruginosa | - | - | nd | - | nd | nd | nd | - | - | - | - | - | - | - |
| Staphylococcus epidermidis | - | nd | nd | - | nd | nd | nd | - | - | - | - | - | - | - |
| Staphylococcus salivarius | - | nd | nd | - | nd | nd | nd | - | - | - | - | - | - | - |
| Staphylococcus aureus | nd | nd | nd | - | nd | nd | - | nd | - | - | - | - | - | - |
| Human immunodeficiency virus type 1,2 | nd | nd | nd | - | nd | nd | nd | nd | - | nd | nd | nd | nd | nd |
| Hepatitis virus (A, B, C) | nd | nd | nd | - | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |

No data available (nd); does not cross-react with analyzed pathogen (-).
3. Emerged Rapid Immunodiagnostic (Serology Immunoassays) Tests

Immunological methods are, most often, the chemiluminescent assaying of immunoglobulin IgG and IgM for SARS-CoV-2 from blood on an analyzer, or immunochromatographic assessment in the form of rapid POCTs, not requiring additional equipment. The methods of detecting anti-SARS-CoV-2 antibodies, despite the ongoing research to develop them further, may or even should be applied during the coronavirus epidemics [22,23]. After about a week from the first clinical manifestations, the sensitivity of molecular diagnostics (PCR) diminishes gradually for SARS-CoV-2 infections, due to the decreasing amount of virus particles in the respiratory tract epithelium. In such cases, patients may have false negative results, despite the ongoing infection.

3.1. Lateral Flow Immunoassay

Among the many contemporary technologies available, special attention should be paid to rapid lateral flow immunoassay (LFIAs), also referred to as immunochromatographic tests. Perhaps they are not so much appreciated in the scientific community as PCR methods or Enzyme-Linked Immunosorbent Assay (ELISA tests), despite the fact that they do find application in diagnostics more and more often. They differ, depending on the type of test, but the basic principle of their action is invariably the same—they make use of the unique property that antibodies possess, that of selective binding to a specific particle or group of similar particles (antigen). LFIAs provide an uncomplicated and relatively inexpensive tool meant for detecting the presence (or absence) of a given component in the examined specimen, such as the presence of a virus in an analyzed blood sample. Examination with the use of those tests is possible for various types of test material—whole human blood, blood plasma, serum, stool, urine, sweat, cerebrospinal fluid, or even tears [9]. The test principle is based on an immunological method, using specific antibodies, most often in complex with colloidal gold, where a drop of the examined substance first moves along the nitrocellulose membrane using capillary phenomena. After the sample is absorbed by the membrane, the antigen (should the test prove to be positive) binds to the colloidal gold complex and respective antibodies. Consequently, the effect of that reaction is the formation of a complex, which will be detected by the test. The interpretation of results consists of confirmation or ruling out of the presence of antigens in the examined sample, based on color test strips that appear in the test [21,22]. The brief comparison of advantages and disadvantages of immunochromatographic tests is presented in Table 4.

Table 4. The brief comparison of advantages and disadvantages of immunochromatographic tests [24–27].

| Advantages | Disadvantages |
|------------|---------------|
| Short reaction time for most tests, amounting to 5–20 min | Suboptimal sensitivity, results often false negative, particularly during enhanced activity of the virus |
| Simple and comfortable to use and perform. Some tests may be performed in outpatient clinics or at patient’s bed. | Despite substantial specificity sometimes the results are false negative, particularly when the virus is not much active. |
| Reading most often possible with ‘naked eye’. | It is necessary to verify positive or doubtful results. |
| Small amount of material to be collected, variety of material. | Increased risk of operator becoming infected |
| “best before” date distant (usually 18 months from manufacturing date) |

At present, most immunoenzymatic tests available are based on the immunochromatic technique. The difference between those tests depends upon the molecule assayed (p/c or antigens), structure, performance time, and diagnostic material. It may be supposed that, in future, rapid tests will enable easier and quicker diagnostics of many diseases, without the necessity of performing tedious and complicated procedures. This would reduce the waiting time for obtaining results, and accelerate decision making regarding suitable treatment [27–29].
3.2. Immunoenzymatic and Immunofluorimetric Assays

The detection of specific SARS-CoV-2 serum antibodies allows for a rapid, cost-effective, and reasonably sensitive clinical diagnosis of COVID-19, as immunoglobulins such as IgM provide the initial humoral response during the first stage of viral infection, prior to the onset of the adaptive, high-affinity IgG response essential for long-term immunological memory. Research indicates that after SARS infection, antibodies of the IgM class may be detected in patient’s blood about 6 days after the infection, while IgG may be already detected after 8 days. As SARS-CoV-2 belongs to the same large family of viruses, which includes those causing Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), it should be assumed that the process of producing antibodies will be similar to that in case of other viruses belonging to that family, while the detection of IgG antibodies and IgM antibodies acting against SARS-CoV-2 may be an indication of infection. Moreover, the detection of IgM antibodies usually indicates a recent exposure to SARS-CoV-2, whereas the detection of IgG antibodies in case of COVID-19 indicates exposure to the virus some time ago [30].

Serological tests, detecting solely the IgM class of antibodies, should find applications for diagnostic purposes. When using tests which detect both IgM and IgG antibodies, one should remember that a positive result may be the evidence of past infection, not active infection (Table 5). Negative results from serological tests do not exclude SARS-CoV-2 infection, as the ‘window period’ (delay in the production of antibodies) may exceed 7 days. Serological tests may also give false positive results. This may be the case of past or ongoing infection with virus strains other than SARS-CoV-2, such as coronavirus HKU1, NL63, OC43, or 229E. Moreover, the first tests assessing the titer of IgA class antibodies have been launched, which, from the perspective of immunology, is of extreme importance, as it provides the possibility of testing for antibodies in a material other than blood samples collected from patients, e.g., respiratory tract secretions.

Serological tests are thus applied as an adjunctive method, for monitoring the epidemiological situation, yet they may be performed faster and are less costly than genetic tests. This diagnostic method has a limited sensitivity, yet efforts to improve it are ongoing, as it is useful for monitoring the infection. Due to insufficient data concerning, among others, the dynamics of immunological response to infection and the diagnostic value of available tests for detecting IgM and IgG class antibodies (comprising sensitivity, specificity, positive and negative predictive value), in many countries, it is currently not recommended to use serological tests for diagnostic purposes. Table 6 displays the evaluation of serological tests validated by the FDA, and Table 7 provides a comparison of the selected immunochromatographic tests for SARS-CoV-2 based on sensitivity, specificity, sample type and test performance time.
Table 6. Evaluations of Coronavirus Disease 2019 (COVID-19) serological tests, including sensitivity, specificity, and predictive value [31] (updated 13 June 2020, online sources according to manufacturers’ pecification).

| Test Name | Euroimmun SARS-COV-2 ELISA (IgG) | Healgen COVID-19 IgG/IgM Rapid Test Cassette | Biomedics COVID-19 IgG/IgM Rapid Test kit | Phamatech COVID19 RAPID TEST | Tianjin Beroni Biotechnology SARS-COV-2 IgG/IgM Antibody Detection Kit |
|-----------|---------------------------------|---------------------------------------------|--------------------------------------------|-------------------------------|---------------------------------------------------|
| Clinical Sensitivity IgM | 100% | 100% | 100% | 100% | 100% |
| Clinical Specificity IgM | 90% | 96.7% | 97.5% | 96.2% | 90% |
| Clinical Sensitivity IgG | 100% | 100% | 97.5% | 96.7% | 100% |
| Clinical Specificity IgG | 100% | 96.7% | 97.5% | 93.8% | 100% |
| Positive Predictive Value at prevalence = 5% (IgM+IgG or IgG) | 100% | 67.8% | 63.7% | 42.4% | 100% |
| Negative Predictive Value at prevalence = 5% (IgM+IgG or IgG) | 99.5% | 100% | 99.8% | 99.3% | 99.5% |

Table 7. Comparison of selected immunochromatographic tests for SARS-CoV-2 based on sensitivity, specificity, sample type and test performance time (updated 13 June 2020, online sources according to manufacturers’ pecification).

| Developer | Test | Sensitivity: | Specificity: | Sample Size | Time (min) |
|-----------|------|--------------|--------------|-------------|------------|
| AcculBioTech Co. Ltd. | Accu-Test COVID-19 IgG/IgM Rapid Test Cassette | IgG 97.4% IgM 86.8% | IgG 99.3% IgM 98.6% | 10 µL of whole blood, serum or plasma | 10 |
| AllTest Biotech Hangzhou | 2019-ncov IgG/IgM Rapid Test Cassette | IgG 100% IgM 85% | IgG 99% IgM 96% | 10 µL of serum or plasma; 20 µL of fingertip blood or whole blood | 10 |
| Aytu Bioscience | COVID-19 IgG/IgM Rapid Test | IgM 89.2% IgG 91.9% | IgM 100% IgG 100% | 5 µL of serum or plasma; 10 µL of whole blood | 2-10 |
| BIOMAXIMA S.A. | 2019-ncov IgG/IgM Rapid Test Cassette | IgG 100% IgM 85% | IgG 99% IgM 96% | 10-20 µL of whole blood, serum or plasma | 10-15 |
| BioMedomics, Inc. | COVID-19 IgM-IgG Dual Antibody Rapid Test | 89% | 91% | 10-20 µL of whole blood, serum or plasma | 10-15 |
| Cell Inc. | Cellex pSARS-CoV-2 IgG/IgM M Cassette Rapid Test | 93.8% | 96.0% | 10 µL of whole blood, serum or plasma | 15-20 |
| Changsha Sinocare Inc. | SARS-CoV-2 Antibody Test Strip (Colloidal Gold Method) | 96.3% Serum/Plasma 95.0% Whole blood | 99.6% Serum/Plasma 99.2% Whole blood | 10 µL of whole blood, serum or plasma | 15-20 |
| CTK Biotech | OrSite COVID-19 IgG/IgM Rapid Test | 96.9% | 99.4% | 10-15 µL of serum or plasma | 10-15 |
| Edinburgh Genetics Limited | Womat COVID-19 Novel Coronavirus antibody detection reagent | - | - | 10 µL of serum or plasma; 20 µL of fingertip blood or whole blood | 15 |
| Getein Biotech, Inc. | One Step Test for Novel Coronavirus (2019-nCoV) IgM/IgG Antibody | 94.1% | 95.1% | 10 µL of serum or plasma; 20 µL of fingertip blood or whole blood | 10-20 |
| Goldsite Diagnostics Inc. | SARS-CoV-2 IgG/IgM Kit | - | - | 30 µL of whole blood | 12 |
| Hangzhou Biotest Biotech | COVID-19 IgG/IgM Rapid Test Cassette | IgM 91.8% IgG 100% | IgM 99.2% IgG 99.5% | 10 µL of whole blood, serum or plasma | 10 |
| Hunan Lituo Biotechnology | COVID-19 IgG/IgM Detection Kit | - | - | - | 15 |
| InTec Products, Inc. | Rapid SARS-CoV-2 Antibody Test IgG or IgM IgG/IgM | 94.4% | 98% | 10 µL of sample | 15-20 |
| Liming Bio-Products Co. Ltd. | COVID-19 IgG/IgM Combo Rapid Test Device | IgG 93.1% IgM 64.7% | IgG 100% IgM 100% | 10 µL of serum or plasma; 20 µL of whole blood | 15 |
Table 7. Cont.

| Developer                      | Test                                                                 | Sensitivity: | Specificity: | Sample Size | Time (min) |
|--------------------------------|----------------------------------------------------------------------|--------------|--------------|-------------|------------|
| Livzon Diagnostic Kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) | 90.6%        | 99.2%        | 10 µL of serum or plasma; 20 µL of whole blood | 15          |
| nal von minden GmbH             | NADAL® COVID-19 IgG/IgM Test                                        | 94.1%        | 99.2%        | 10 µL of whole blood, serum or plasma | 10          |
| Nanjing Vazyme Medical Tech.    | 2019-nCoV IgG/IgM Detection Kit                                     | 91.54%       | 97.02%       | 20 µL of whole blood, serum or plasma | 15          |
| PRIMA Lab S.A.                  | PRIMA COVID-19 IgG/IgM Rapid Test (For Professional Use)            | -            | -            | 10 µL of serum or plasma; 20 µL of fingertip blood or whole blood | 20          |
| Stagentech, Inc                | SGTi-flex COVID-19 IgM/IgG                                          | 90%-92%      | 96%-98%      | 10 µL whole blood | 10          |
| Sensing Self,                  | COVID-19 Rapid IgG/IgM combined Antibody assay                       | IgM 92%; IgG 100% | IgM 97.58%; IgG 99.31% | 20 µL of fingertip blood or whole blood | 10          |
| Xiamen AmonMed Biotechnology   | COVID-19 IgM/IgG test kit                                           | IgM 78.43%; IgG 84.31% | IgM 98.40%; IgG 99.20% | -          | 15          |
| Coris BioConcept               | COVID-19 Ag Respi-Strip                                              | 60%          | 98%-100%     | 100 µL extract | 15          |
| RapiGEN, Inc.                  | BIOCREDIT COVID-19 Ag                                               | 89.4%        | 98%          | 90–150 µL extract | 5–8         |
| SD BIOSENSOR                   | STANDARD Q COVID-19 Ag Test                                          | 84%          | 100%         | 10 µL extract | 15–30       |
| VivaChek Laboratories,         | VivaDiagTM COVID-19 IgG/IgM Rapid Test                              | 100%         | IgM and IgG: 97.1% | 10 µL of whole blood, serum or plasma | 15          |
| Qingdao Hightop Biotech        | SARS-CoV-2 IgM/IgG Antibody Rapid Test                              | IgG 93%; IgM 82% | IgG 97.5%; IgM 96% | 10 µL of serum or plasma; 20 µL of whole blood | 15–20       |
| Novazym                       | Wuhan Coronavirus Rapid Test (2019-nCoV, COVID-19) IgG/IgM           | IgG 91.8%; IgM 95.7% | IgG 96.4%; IgM 97.3% | 5 µL of serum or plasma | 15          |

In serological IVD, the so-called ‘window period’ is of much importance—that is, the time when specific antibodies are not yet detectable in a patient’s blood. In the initial phase of an infection, the production of antibodies is initiated, but their level is still low, and thus test results may prove negative. Anti-SARS-CoV-2 antibodies appear quite late, i.e., a few days after clinical manifestations, which is why serological tests cannot be used as a basic tool in diagnosing SARS-CoV-2 infections [32].

The detection of specific anti-SARS-CoV-2 antibodies is possible about 10 days after the first clinical manifestations of infection. Thus, this serves the purpose of confirming contact with coronavirus, and is of enormous importance from an epidemiological perspective, as it allows us to detect subjects who had the infection but were asymptomatic or oligosymptomatic, and could have been the source of infection for other people (“silent” carriers/vectors). It also allows us to determine the spread of COVID-19 infection in the population. A comparative review of currently available serological immunodiagnostic COVID-19 tests is presented in Table 8.
| Test Type          | Developer                                | Test                                                                 | Molecule                        | Materials                  | Status          |
|-------------------|------------------------------------------|----------------------------------------------------------------------|---------------------------------|----------------------------|-----------------|
| Immunochromatographic          | AccuBioTech Co. Ltd.                      | Accu-Tell COVID-19 IgG/IgM Rapid Test Cassette                        | IgG or IgM or both              | Whole blood/serum/plasma | CE              |
|                   | BIOMAXIMA S.A.                           | 2019-nCoV IgG/IgM Rapid Test Cassette                                 |                                 |                            | CE-IVD          |
|                   | BioMedomics, Inc.                        | COVID-19 IgM-IgG Dual Antibody Rapid Test                             |                                 |                            | CE-IVD          |
|                   | Cellex Inc.                              | Cellex gSARS-CoV-2 IgG/IgM Cassette Rapid Test                        |                                 |                            | CE              |
|                   | Changsha Sinocare Inc.                   | SARS-CoV-2 Antibody Test Strip (Colloidal Gold Method)                |                                 |                            | CE-IVD          |
|                   | Edinburgh Genetics Limited               | Wattman 2019 nCoV novel coronavirus antibody detection reagent        |                                 |                            | CE              |
|                   | Gatein Biotech, Inc.                     | One Step Test for Novel Coronavirus (2019-nCoV) IgM/IgG Antibody      |                                 |                            | CE              |
|                   | Goldsite Diagnostics Inc.                | SARS-CoV-2 IgG/IgM Test                                               |                                 |                            | CE-IVD          |
|                   | Hanan Lituo Biotechnology                | COVID-19 IgG/IgM Detection Kit                                        |                                 |                            | CE-IVD          |
|                   | Innovita Biological Technology          | 2019-nCoV Ab Test (Colloidal Gold) IgM/IgG                            |                                 |                            | CE-IVD; China, Brazil |
|                   | InTec Products, Inc.                     | Rapid SARS-CoV-2 Antibody Test IgG or IgM or IgG                     |                                 |                            | CE-IVD          |
|                   | Liming Bio-Products Co., Ltd.            | COVID-19 IgG/IgM Combo Rapid Test Device                              |                                 |                            | CE              |
|                   | nald von minden GmbH                     | NADAL® COVID-19 IgG/IgM Test                                          |                                 |                            | CE-IVD          |
|                   | PRIMA Lab S.A.                           | PRIMA COVID-19 IgG/IgM Rapid Test (For Professional Use)              |                                 |                            | CE              |
|                   | Dynamiker Biotechnology (Tianjin) Co., Ltd.| 2019 nCOV IgG/IgM Rapid Test                                         |                                 |                            | CE-IVD          |
|                   | Coris BioConcept                         | COVID-19 Ag Respi-Strip                                               |                                 |                            | CE-IVD          |
|                   | RapiGEN, Inc.                            | BIOCREDIT COVID-19 Ag Set                                             |                                 |                            | CE-IVD, Brasil  |
|                   | SD BIOSENSOR, Inc.                       | STANDARD Q COVID-19 Ag Test                                           |                                 |                            | CE-IVD          |
| ELISA             | DRG International, Inc.                  | COVID-19 IgG, EIA-6146                                                |                                 |                            | CE-IVD          |
|                   | Epitope Diagnostics, Inc.                | EDP™ Novel Coronavirus COVID-19 IgG ELISA Kit                          | IgG                             | Serum                      | CE-IVD          |
|                   | EUROIMMUN AG                             | Anti-SARS-CoV-2 ELISA (IgG)                                          |                                 |                            | CE-IVD; Brazil  |
|                   | DRG International, Inc.                  | COVID-19 IgM, EIA-6147                                                | IgM                             | Serum                      | CE-IVD          |
|                   | Epitope Diagnostics, Inc.                | EDP™ Novel Coronavirus COVID-19 IgM ELISA Kit                          |                                 |                            | CE-IVD          |
|                   | EUROIMMUN AG                             | Anti-SARS-CoV-2 ELISA (IgA)                                          | IgA                             | Serum                      | CE-IVD          |
|                   | SD BIOSENSOR, Inc.                       | STANDARD F COVID-19 Ag FIA                                            |                                 |                            | CE-IVD, Brasil  |
| immunoFLuorescent | Shenzhen Bioeasy Biotechnology Co., Ltd.  | Bioeasy 2019-nCoV Ag Fluorescence Rapid Test Kit                       |                                 |                            | CE-IVD          |
|                   | Mokolito Biotechnology R&D Center        | SARS-CoV-2 IgM & IgG Quantum Dot Immunoassay                          | IgG/IgM                         | Serum, plasma, whole blood | CE-IVD          |
| Proteome Microarray | PEPperPRINT GmbH                        | PEPlpPERCHIP® SARS-CoV-2 Proteome Microarray (manual)                 |                                 |                            | Proteome       |
3.3. Protein Microarray Method (PMM)

The protein microarray method (PMM) is a proteomic screening technique serving the purpose of simultaneous/parallel quantitative and qualitative analysis of mixtures containing many proteins. The chip used is composed of a supporting surface (e.g., modified glass plate, nitrocellulose membrane, or microtitration plate), on which the matrix of ‘capturing’ proteins is immobilized in accordance with the determined formula, performing the function of a probe. The material captured may be antibodies, enzymes, or ligands. Protein analyte, added to the matrix, may be modified by means of various types of markers (among others: radioisotopes, fluorescence, luminescence markers). The interaction between micromatrix proteins and analyte induces an analytical signal, registered by means of suitable equipment. The advantages of protein micromatrices include the short time required for analysis, modest consumption of samples and reagents, high sensitivity, automation of testing. They allow us to investigate the functions and effects of proteins on large scale [33,34].

The newly developed PEPperCHIP® SARS-CoV-2 Proteome Microarray (PEPperPRINT) based on the SARS-CoV-2 genome derived from the virus isolate Wuhan-Hu-1 (GenBank ID: MN908947.3) enables us to serologically screen about 5000 individual peptides spanning the whole viral proteome. Sequences of ORF1ab protein, surface glycoprotein, ORF3a protein, coat protein, membrane glycoprotein, ORF6 protein, ORF7a protein, ORF8 protein, nucleocapsid phosphoprotein, and ORF10 protein have been elongated and connected by means of neutral GSGSGSG connectors. The elongated protein sequences have been transcribed into 4883 different peptides composed of 15 amino acids printed in two repetitions (9766 peptide sites) in order to obtain high-resolution epitope data. In the case of SARS-CoV, which emerged in 2002, it was demonstrated that the application of PMM is characterized by enhanced sensitivity, as more Chinese subjects were diagnosed as SARS-positive when applying PMM in comparison with ELISA tests. The PMM seems to be more reliable, as it allows us to determine more protein antigens of the virus [35]. An additional advantage of such tests is the possibility of automating the entire analytical process. Unfortunately, the method has several imperfections, including the repeatability of the test itself, while the cost of the testing and equipment used for micromatrix diagnostics is significant, which makes the PMM method less accessible in standard laboratory settings [36].

Undoubtedly, the scalable and reliable POCTs used in the community and outside laboratories would have the opportunity to reduce the time to obtain COVID-19 diagnostic results and might support early implementation of isolation resources and infection control measures. From a medical workforce point of view, antibody- and antigen-detecting tests appear to have a significant role in identifying healthcare workers who recovered from SARS-CoV-2 infection, to assess their suitability to provide frontline health services. On the other hand, the false negative serology tests could cause spread of COVID-19, unjustified reassurance and a change in public behavior. Undoubtedly, the negative results of serology tests (swabs) should not be treated as definitive for ‘ruling out’, but a positive test results are beneficial to ‘rule in’ coronavirus infection. The sufficient accuracy of serology tests used more widely will allow us to make an appropriate decision regarding lifting restrictions on a national level. Nevertheless, the wider implementation of POCD will ultimately support public health strategies about the potential lifting of social distancing restrictions in future [30]. Moreover, with the limited data available at present, for antibody-detecting and antigen-detecting rapid POCD, further intense research into their potential diagnostic utility is highly encouraged. If these tests demonstrate adequate accuracy, it is likely that they could potentially be used as triage tests for quick identification of patients who are suspected of contracting COVID-19, reducing the need for expensive reference molecular PCR testing [4,6]. Finally, it is worth noting the psychological and behavioral consequences of correctly established and known immunity status within the community.
4. The Currently Developing Concepts of COVID-19 Diagnostics

4.1. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas13) Technology

Recently, a test has been developed based on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR/Cas12a), with visual readouts. The test can detect 10 copies of the virus gene in merely 45 min, providing simple and reliable diagnostic method, which additionally demonstrates high sensitivity and specificity. In order to enable fast diagnosis at the hospital or on admission, the test has been provided with an ssDNA reporter labeled with a blank green fluorescent particle, which will be split off by the Cas12a protein, when the nucleic acid of SARS-CoV-2 is found in the detection system. In this way, a green signal of fluorescence will be obtained, visible with the naked eye, in the light, with a wavelength of 485 nm. The high specificity of the test was obtained by designing 15 crRNAs, which may distinguish the polymorphisms of a single nucleotide with other viruses related to SARS in four domains: ORF1a or ORF1b, N, and E genes [37].

4.2. Exhaled Breath Condensate (EBC)

The search for new diagnostic methods is continued. Because SARS-CoV-2 is spread by droplets, while the diagnostic sensitivity and specificity index for RT-qPCR tests is the highest for broncho-alveolar lavage (BAL) (higher than for sputum or nose/throat swabs), scientists recently proposed the use of exhaled breath condensate (EBC) for diagnostic purposes. EBC is most similar in its biochemical composition and origin to BAL. Examinations with the use of EBC are a relatively novel diagnostic method, used mainly to assess inflammation within the respiratory tract, and its components reflect the composition of the fluid lining the bronchi and alveoli. EBC is a condensed form of small droplets of the fluid lining the lungs, which is usually exhaled, it contains various components, from small ions to proteins and organelles; it may even contain viruses, fungi, and bacteria. Taking samples of the condensate is safe, totally non-invasive, easy to perform, it may be repeated many times, it may also be performed on patients with severe complications of COVID-19; its enormous advantage is that in may be performed in small children, with the use of special facial masks. The course of the examination is such that the patient is requested to exhale, when breathing uneventfully for some 10-15 min, to an apparatus provided with a cooling system, which allows us to accumulate the condensate in which SARS-CoV-2 may be detected. The application of this method seems justified from a public health perspective. The false positive results that are presently obtained contribute the continued spread of the virus worldwide [38,39].

5. Conclusions

The optimization of laboratory diagnostics is the most dynamically developing field in the time of the COVID-19 pandemic, supporting contemporary medicine, government decisions and healthcare strategies. The efforts of scientist–clinician teams focus, first of all, upon implementing the most reliable diagnostic tools; however, because COVID-19 is a new nosological entity, there are not enough data as of yet that would enable the determination of standards for the interpretation of serological POCTs. As with any other infectious diseases, the diagnostic value of a test is not only about the method of collecting the material, the quality of the sample and the equipment applied. Equally essential pre-analytical considerations are also the time point when a sample is collected, as well as a suitable procedure (storage and handling) prior to analysis, from the moment of collecting the biological material to the assaying stage.

Author Contributions: Conceptualization, R.K., A.D.; formal analysis, R.K.; resources, R.K., A.D.; writing—original draft preparation, R.K.; writing—review and editing, A.D.; visualization, R.K., A.D. Both authors have read and agreed to the published version of the manuscript.

Funding: This study received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Lau, S.K.P.; Woo, P.C.Y.; Yip, C.C.Y.; Tse, H.; Tsoi, H.; Cheng, V.C.C.; Lee, P.; Tang, B.S.F.; Cheung, C.H.Y.; Lee, R.A.; et al. Coronavirus HKU1 and Other Coronavirus Infections in Hong Kong. J. Clin. Microbiol. 2006, 44, 2063–2071. [CrossRef] [PubMed]

2. Singhal, T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J. Pediatr. 2020, 87, 281–286. [CrossRef] [PubMed]

3. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: https://coronavirus.jhu.edu/map.html (accessed on 13 June 2020).

4. World Health Organization. Advice on the Use of Point-Of-Care Immunodiagnostic Tests for COVID-19. Available online: https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19 (accessed on 13 June 2020).

5. Corman, V.; Bleicker, T.; Brünink, S.; Drosten, C.; Landt, O.; Koopmans, M.; Zambon, M. Diagnostic Detection of 2019-nCoV by Real-Time RT-PCR. Protocol and Preliminary Evaluations of 17 January 2020. Available online: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2. (accessed on 23 June 2020).

6. Lu, W.; Liu, L.; Kou, G.; Zheng, Y.; Ding, Y.; Ni, W.; Wang, Q.; Tan, L.; Wu, W.; Tang, S.; et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. J. Clin. Microbiol. 2020, 58, e00461-20. [CrossRef]

7. Corman, V.M.; Bleicker, T.; Brünink, S.; Drosten, C.; Landt, O.; Koopmans, M.; Zambon, M. Diagnostic Detection of 2019-nCoV by Real-Time RT-PCR. Eurosurveillance 2020, 25, 200045. [CrossRef]

8. Vashist, S.K. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics 2020, 10, 202. [CrossRef]

9. Shereen, M.A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J. Adv. Res. 2020, 24, 91–98. [CrossRef] [PubMed]

10. Diagnostic Detection of Wuhan Coronavirus 2019 by Real-Time RT-PCR. Available online: https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a17c111902.pdf (accessed on 13 June 2020).

11. COVID-19 Diagnostics Resource Centre. Available online: https://www.finddx.org/covid-19/ (accessed on 13 June 2020).

12. Deepak, S.A.; Kottapalli, K.R.; Rakwal, R.; Oros, G.; Rangappa, K.S.; Iwahashi, H.; Masuo, Y.; Agrawal, G.K. Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes. Curr. Genom. 2007, 8, 234–251. [CrossRef] [PubMed]

13. Rapid Test for COVID-19 (SARS-CoV-2). Available online: https://www.bosch-vivalytic.com/en/product/vivalytic-tests/vri-multiplex-test/ (accessed on 9 May 2020).

14. SARS-CoV-2 Real Time PCR LAB-KIT™. Available online: https://www.biomaxima.com/736-koronavirus-sars-cov-2.html (accessed on 28 April 2020).

15. Novel Corona Virus SARS-CoV-2 (COVID-19). Available online: http://www.ox.ac.uk/news/2020-03-18-oxford-scientists-develop-rapid-testing-technology-covid-19 (accessed on 9 May 2020).

16. Huang, W.E.; Lim, B.; Hsu, C.C.; Xiong, D.; Wu, W.; Yu, Y.; Jia, H.; Wang, Y.; Zeng, Y.; Ji, M.; et al. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. Microb. Biotechnol. 2020, 13, 950–961. [CrossRef]

17. Chen, P.; Beavis, K.G.; Matushek, S.M.; Ciaglia, C.; Francois, N.; Tesic, V.; Love, N. The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays. J. Clin. Microbiol. 2020. [CrossRef] [PubMed]

18. Waterson, J.; Whiting, P.F.; Brush, J.E. Interpreting a covid-19 test result. BMJ 2020, 369, m1808. [PubMed]

19. West, C.P.; Montori, V.M.; Sampathkumar, P. COVID-19 Testing: The Threat of False-Negative Results. Mayo Clin. Proc. 2020. [CrossRef]
22. Lippi, G.; Salvagno, G.L.; Pegoraro, M.; Militello, V.; Caloi, C.; Peretti, A.; Gaino, S.; Bassi, A.; Bovo, C.; Lo Cascio, G. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin. Chem. Lab. Med. 2020. [CrossRef]

23. Hsueh, P.R.; Huang, L.M.; Chen, P.J.; Kao, C.L.; Yang, P.C. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin. Microbiol. Infect. 2004, 10, 1062–1066. [CrossRef]

24. Guan, M.; Chen, H.Y.; Foo, S.Y.; Tan, Y.J.; Goh, P.Y.; Wee, S.H. Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients. Clin. Diagnost. Lab. Immunol. 2004, 11, 287–291. [CrossRef]

25. Kogaki, H.; Uchida, Y.; Fujii, N.; Kurano, Y.; Miyake, K.; Kido, Y.; Kariwa, H.; Takashima, I.; Tamashiro, H.; Ling, A.-E.; et al. Novel rapid immunochromatographic test based on an enzyme immunoassay for detecting nucleocapsid antigen in SARS-associated coronavirus. J. Clin. Lab. Anal. 2005, 19, 150–159. [CrossRef]

26. Koczula, K.M.; Gallotta, A. Lateral flow assays. Essays Biochem. 2016, 60, 111–120.

27. Oh, J.-S.; Ha, G.-W.; Cho, Y.-S.; Kim, M.J.; An, D.J.; Hwang, K.K.; Lim, Y.K.; Park, B.K.; Kang, B.; Song, D.S. One Step Immunochromatography Assay Kit for Detecting Antibodies to Canine Parvovirus. Clin. Vaccine Immunol. 2006, 13, 520–524. [CrossRef]

28. Posthuma-Trumpie, G.A.; Korf, J.; van Amerongen, A. Lateral flow (immuno)assay: Its strengths, weaknesses, opportunities and threats. A literature survey. Anal. Bioanal. Chem. 2009, 393, 569–582. [CrossRef]

29. Stürenburg, E.; Junker, R. Point-of-care testing in microbiology: The advantages and disadvantages of immunochromatographic test strips. Disch. Arztebl. Int. 2009, 106, 48–54. [PubMed]

30. Li, Z.; Yi, Y.; Luo, X.; Xiong, N.; Liu, Y.; Li, S.; Sun, R.; Wang, Y.; Hu, B.; Chen, W.; et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J. Med. Virol. 2020. [CrossRef] [PubMed]

31. Independent Evaluations of COVID-19 Serological Tests. Available online: https://open.fda.gov/apis/device/covid19serology/ (accessed on 13 June 2020).

32. Lauer, S.A.; Grantz, K.H.; Bi, Q.; Jones, E.K.; Zheng, Q.; Meredith, H.R.; Azman, A.S.; Reich, N.G.; Lessler, J. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Intern. Med. 2020. [CrossRef]

33. Melton, L. Protein arrays: Proteomics in multiplex. Nature 2004, 429, 101–107. [CrossRef]

34. Hall, D.A.; Ptacek, J.; Snyder, M. Protein microarray technology. Mech. Ageing. Dev. 2007, 128, 161–167. [CrossRef] [PubMed]

35. Zhu, H.; Hu, S.; Jona, G.; Zhu, X.; Kreiswirth, N.; Willey, B.M.; Mazzulli, T.; Liu, G.; Song, Q.; Chen, P.; et al. Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray. Proc. Natl. Acad. Sci. USA 2006, 103, 4011–4016. [CrossRef] [PubMed]

36. Molecular and Antibody Point-Of-Care Tests to Support the Screening, Diagnosis and Monitoring of COVID-19. Available online: https://www.cebm.net/covid-19/molecular-and-antibody-point-of-care-tests-to-support-the-screening-diagnosis-and-monitoring-of-covid-19/ (accessed on 13 June 2020).

37. Wang, X.; Zhong, M.; Liu, Y.; Ma, P.; Dang, L.; Meng, Q.; Wan, W.; Ma, X.; Liu, J.; Yang, G.; et al. Rapid and Sensitive Detection of COVID-19 Using CRISPR/Cas12a-based Detection with Naked Eye Readout, CRISPR/Cas12a-NER. Sci. Bull. (Beijing) 2020. [CrossRef]

38. Khoubnasabjafari, M.; Jouyban-Gharamaleki, V.; Ghanbari, R.; Jouyban, A. Exhaled breath condensate as a potential specimen for diagnosing COVID-19. Bioanalysis 2020. [CrossRef]

39. Jerzyńska, J.; Brzozowska, A.; Bobrowska-Korzeniowska, M.; Grzelewski, T.; Stelmach, I. Usefulness of exhaled breath condensate for evaluation of markers of airway inflammation in children with asthma. Pediatr. Pol. 2009, 84, 437–445. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).